Company: PIII
Filing Date: 2025-04-18
Form Type: PRE 14A
Source: 0001140361-25-014596
Chunk: 23

Company: P3 Health Partners Inc.
Filing Date: 2025-04-18
Form: PRE 14A
Chunk 23
---
 approval of the compensation of our named executive officers, as disclosed in this Proxy Statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission, including the compensation tables and narrative discussion. Vote Required This proposal requires the approval of the affirmative vote of the majority of the votes cast. Abstentions and broker non-votes will have no effect on this proposal. Recommendation of theBoard of Directors

| The Board of Directors unanimously recommends a vote FOR the approval, on an advisory (non-binding) basis, of the compensation of the named executive officers, as disclosed in this Proxy 
 Statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission, including the compensation tables and narrative discussion.                             |

14 Proposal 4: Approval, in accordance with Nasdaq Listing Rule 5635(d), of the issuance of up to 1,428,129 shares of Class A common stock upon the exercise of outstanding Class A common stock warrants held by VBC Growth SPV 4, LLC The Company is asking stockholders to approve the issuance of up to 1,428,129 shares of Class A common stock (as adjusted for the Reverse Stock Split) upon the exercise of outstanding Class A common stock warrants held by VBC Growth SPV 4, LLC (“VBC 4”), for purposes of Nasdaq Listing Rule 5635(d), as described in more detail below. General Background of the 2025 Financing On February 13, 2025, P3 Health Group, LLC (“P3 LLC”), our subsidiary, entered into a financing transaction with VBC 4, consisting of an unsecured promissory note (the “Promissory Note”) and warrants (the “VBC 4 Warrants”) to purchase up to 1,428,129 shares of Class A Common Stock (the “2025 Financing”). VBC 4 is a Delaware limited liability company managed by Chicago Pacific Founders GP III, L.P. (“CPF GP III”), an affiliate of the principal stockholder of the Company. The entry into the Promissory Note and the issuance of the Warrants was approved by a committee of independent, disinterested directors of the Company. VBC 4 Promissory Note The Promissory Note was issued by P3 LLC to VBC 4 on February 13, 2025, and provided for funding of up to $30.0 million, available for draw by P3 LLC in two tranches, as follows: (i) a first tranche of $15.